Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-HER2 Affibody in Breast and Gastric Tumors
NCT05411432Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2023
01
Overview
Phase 1, open-label trial (2 arms), sponsored by Xijing Hospital. Primary endpoint: Standard Uptake Value of organs at 4 hours. Status: unknown.
Beyond the preview
Go deeper on NCT05411432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411432.